ORAI1 and hepatocellular carcinoma: In 2013, Louandre et al. demonstrated that sorafenib induces ferroptosis in hepatocellular carcinoma (HCC) cells, and triggering ferroptosis may improve the antitumor effect of sorafenib in HCC (Louandre et al., 2013); Henke et al. (2013) found that dysregulated ORAI1-mediated Ca2+ influx contributes to ferroptosis in HT22 cells; based on their previous research, Speer et al. (2013) suggested that iron chelators inhibit ferroptosis in primary neurons by targeting the HIF prolyl hydroxylases.